Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Modalis Therapeutics Corporation ( (JP:4883) ) just unveiled an announcement.
Modalis Therapeutics announced the granting of a Japanese patent for its MDL-101 gene therapy, targeting Laminin alpha-2–Congenital Muscular Dystrophy (LAMA2-CMD) using its CRISPR-GNDM® technology. This patent strengthens Modalis’ intellectual property rights, supporting its lead program and potentially paving the way for patents in other major countries, reinforcing its market position in treating orphan genetic diseases.
More about Modalis Therapeutics Corporation
Modalis Therapeutics Corporation is a developer of precision genetic medicines, focusing on epigenome editing technology. The company specializes in therapies for orphan genetic diseases using its proprietary CRISPR-GNDM® technology, which allows for specific gene expression modulation without altering DNA sequences. Modalis is headquartered in Tokyo, with research and development operations in Waltham, Massachusetts, and is listed on the Tokyo Stock Exchange’s Growth market.
YTD Price Performance: -2.94%
Average Trading Volume: 15,218,647
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen6.87B
Learn more about 4883 stock on TipRanks’ Stock Analysis page.